RRM2
Ribonucleoside-diphosphate reductase subunit M2
As of the edition of 20 October 2026, RRM2 (ribonucleoside-diphosphate reductase subunit M2, UniProt P31350) has 9 drugs tested at it and 18 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P31350
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 5
- Disease areas
- Blood and lymph; Cancer; Inherited and neonatal; Immune system; Nervous system; Urinary and reproductive; Infections; Lungs and airways
- Registered trials of its drugs
- 236
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 2 |
| Went quiet | 3 |
| Stopped | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Hydroxyurea | Marketed | Phase 4 | none listed |
| Motexafin gadolinium | Stopped | Phase 3 | none listed |
| GTI-2040 | Went quiet | Phase 2 | none listed |
| TAR-200 | Active | Phase 3 | none listed |
| Gallium nitrate | Marketed | Phase 2 | none listed |
| Gallium citrate | Marketed | Phase 3 | none listed |
| Tezacitabine anhydrous | Went quiet | Phase 2 | none listed |
| FF-10832 | Active | Phase 2 | none listed |
| Osalmid | Went quiet | Phase 2 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Engaged | 7 |
| Undetermined | 8 |
| Total on the list | 18 |
| Company | Route |
|---|---|
| Chapter 7 Trustee Of Genta | Route B |
| Theravia | Route B |
| Aptose Biosciences | Route A |
The other 15 companies at RRM2
In the product18 companies in all; 15 are not named here, and no score is.
See the 18 companies at RRM2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.